Compare TG & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | VANI |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 100.0M |
| IPO Year | 1994 | 2014 |
| Metric | TG | VANI |
|---|---|---|
| Price | $7.79 | $1.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 189.9K | 184.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $800,821,000.00 | $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.94 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $6.25 | $0.92 |
| 52 Week High | $10.53 | $1.92 |
| Indicator | TG | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 60.62 |
| Support Level | $7.31 | $1.24 |
| Resistance Level | $8.04 | $1.34 |
| Average True Range (ATR) | 0.44 | 0.06 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 20.35 | 100.00 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.